Jyong Biotech Plans New Manufacturing Facility in Texas
The proposed facility aims to support U.S. operations for the biotech firm, signaling new opportunities for regional suppliers.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you support your state offering tax incentives to attract new pharmaceutical manufacturing facilities?
Jyong Biotech has submitted a facility and operations plan to Texas state authorities as it looks to establish its first U.S. manufacturing base. The company, which currently has no commercial drug products on the market, is targeting the state for its favorable tax structure and manufacturing incentives.
Why it matters
The proposed facility is intended to provide domestic infrastructure for future commercialization efforts as the company prepares to move its drug candidates into the U.S. market. For Texas business operators, the development highlights ongoing state efforts to attract life sciences manufacturing through land and tax advantages.
The firm, established in 2002, enters a market managing 12.2 million men for BPH/LUTS, a figure drawn from 2015 data. Industry analysts note that 54.8% of these patients currently use chemical medications, while 35% are in watchful waiting and 9.1% have discontinued therapy.
The players
Jyong Biotech
A Taiwan-based firm founded in 2002 that specializes in pharmaceutical research and is currently seeking to establish U.S. production.
The details
Jyong Biotech selected Texas after evaluating land costs, logistical support, and available tax exemptions for manufacturers. The company is now preparing to initiate formal communications with state agencies to advance the project. The planned facility is expected to include pharmaceutical manufacturing capabilities and is currently being evaluated for potential health supplement production lines.
Timeline
2002: Company inception.
2015: Reported data on U.S. men managed for BPH/LUTS.
October 15, 2026: Company announced proposed Texas facility.
Market Landscape
Jyong Biotech's project follows a long-standing pattern of international firms leveraging state-level tax structures to establish U.S. operations. The facility signals a shift toward local manufacturing for firms seeking to lower capital entry barriers for pharmaceutical distribution.
Texas-based logistics and construction operators should monitor future announcements regarding the facility's specific location and scope. Owners should track the firm's progress as it moves from planning to agency communication, as this represents a new potential client for local industrial services.
The takeaway
This entry highlights the ongoing expansion of international life sciences manufacturing into the state and the importance of analyzing regional tax incentives when planning new facilities. Operators should monitor the progress of these types of large-scale site selections to identify new subcontracting opportunities.
Further reading
For more on industry shifts and investment in the region, see Healthcare.
Live Poll
Do you support your state offering tax incentives to attract new pharmaceutical manufacturing facilities?
